Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism

Detalles Bibliográficos
Autores principales: Papadopoulos, Konstantinos, Papadopoulou, Alexandra, Aw, Tar Choon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tabriz University of Medical Sciences 2023
Materias:
Letter to Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460798/
https://www.ncbi.nlm.nih.gov/pubmed/37646061
http://dx.doi.org/10.34172/apb.2023.045
_version_ 1785097713026596864
author Papadopoulos, Konstantinos
Papadopoulou, Alexandra
Aw, Tar Choon
author_facet Papadopoulos, Konstantinos
Papadopoulou, Alexandra
Aw, Tar Choon
author_sort Papadopoulos, Konstantinos
collection PubMed
description
format Online
Article
Text
id pubmed-10460798
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Tabriz University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-104607982023-08-29 Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism Papadopoulos, Konstantinos Papadopoulou, Alexandra Aw, Tar Choon Adv Pharm Bull Letter to Editor Tabriz University of Medical Sciences 2023-07 2022-09-18 /pmc/articles/PMC10460798/ /pubmed/37646061 http://dx.doi.org/10.34172/apb.2023.045 Text en ©2023 The Authors. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.
spellingShingle Letter to Editor
Papadopoulos, Konstantinos
Papadopoulou, Alexandra
Aw, Tar Choon
Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title_full Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title_fullStr Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title_full_unstemmed Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title_short Fluvoxamine Mediates Specific, Early, and Delayed SARS-CoV-2 Protection through Antioxidant and Cytoprotective Pathways via Sigma-1 Receptor Agonism
title_sort fluvoxamine mediates specific, early, and delayed sars-cov-2 protection through antioxidant and cytoprotective pathways via sigma-1 receptor agonism
topic Letter to Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10460798/
https://www.ncbi.nlm.nih.gov/pubmed/37646061
http://dx.doi.org/10.34172/apb.2023.045
work_keys_str_mv AT papadopouloskonstantinos fluvoxaminemediatesspecificearlyanddelayedsarscov2protectionthroughantioxidantandcytoprotectivepathwaysviasigma1receptoragonism
AT papadopouloualexandra fluvoxaminemediatesspecificearlyanddelayedsarscov2protectionthroughantioxidantandcytoprotectivepathwaysviasigma1receptoragonism
AT awtarchoon fluvoxaminemediatesspecificearlyanddelayedsarscov2protectionthroughantioxidantandcytoprotectivepathwaysviasigma1receptoragonism

Ejemplares similares